{
    "nctId": "NCT03008005",
    "officialTitle": "Effects of THC on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study",
    "inclusionCriteria": "* Able to give informed consent\n* Right-handed\n* Age between 18-50 years old,\n* Physically and neurologically healthy \\[confirmed by a comprehensive medical history\\]\n* Current PTSD diagnosis\n* Must have minimum age of 18 Years\n* Must have maximum age of 50 Years",
    "exclusionCriteria": "* clinically significant medical or neurologic condition or neurocognitive dysfunction that would affect function and/or task performance and/or interfere with the study protocol\n* any current (or within past 2 months) medical condition requiring medication that would interact with dronabinol or interfere with the study protocol\n* risk of harm to self or others that requires immediate intervention\n* presence of contraindications, current or past allergic or adverse reaction, or known sensitivity to cannabinoid-like substances (dronabinol/marijuana/cannabis/THC, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide)\n* lack of fluency in English\n* positive drug screen or alcohol breathalyzer\n* unwilling/unable to sign informed consent document\n* currently pregnant (positive pregnancy test), planning pregnancy, or lactating (women)\n* under 18 or over 50 years of age\n* traumatic brain injury (as defined by The American Congress of Rehabilitation as a person who has had a traumatically induced physiological disruption of brain function (i.e., the head being struck, the head striking an object, and/or the brain undergoing an acceleration/deceleration movement (i.e., whiplash) without direct external trauma to the head), as manifested by at least one of the following: any loss of consciousness; any loss of memory for events immediately before or after the injury; any alteration in mental status at the time of the incident; or focal neurological deficits that may or may not be transient)\n* inability to tolerate small, enclosed spaces without anxiety (e.g. claustrophobia), as determined by self-report and/or a preliminary session in a mock scanner\n* left-handed;\n* presence of ferrous-containing metals within the body (e.g., aneurysm clips, shrapnel/retained particles)\n* anticipation of a required drug test in the 4 weeks following the study.\n* current diagnosis of a mood, anxiety, or other disorder that is more clinically salient than PTSD\n* current moderate or severe alcohol/drug use disorder or in the past 8 weeks\n* current or past diagnosis of bipolar and other related disorders, schizophrenia spectrum, or other psychotic disorders\n* concomitant treatments with medication known to have drug interactions with dronabinol, such as, central nervous system depressants (barbiturates, benzodiazepines, buspirone, lithium, etc) and anticholinergic agents (atropine, scopolamine, antihistamines, etc)."
}